Imaginostics
BioTech/Drugs - Cambridge, MA, US
Imaginostics Employees
Imaginostics Senior Management
Imaginostics Details
Imaginostics is a Boston-based health tech startup developing revolutionary magnetic resonance imaging (MRI) biomarkers for the early diagnosis of complex diseases, such as Alzheimer's Disease and Related Dementias.The company's proprietary QUTE-CE MRI software suite is a breakthrough in precision medicine that works with existing MRI scanners. Data can be used to stratify patient populations, provide early preventative diagnostics, and assess drug efficacy in clinical trials.Founder and CEO, Dr. Codi Gharagouzloo, invented the Quantitative Ultra-short Time-to-echo Contrast-Enhanced (QUTE-CE) MRI method while completing his Ph.D. in Bioengineering at Northeastern University. He furthered his research during a postdoctoral fellowship at the Gordon Center for Medical Imaging at Massachusetts General Hospital and Harvard Medical School.Imaginostics currently offers the following software and services:• Safe Full Body Vascular Enhanced Imaging for Renally Impaired Patients • Neurological Drug Characterization (Vascular Function, Density and Structure)• Biomarkers for Alzheimer's Disease and Related Dementias (ADRD)• Cancer Biomarkers• Cardiovascular Biomarkers• Kidney BiomarkersPlease reach out if you would like to explore opportunities to work together: • Pharmaceutical Companies• Hospitals• Academic Research Collaborators• Investors
Imaginostics Technologies
Email Providers
Gmail
Event Management
Eventbrite
CMS
WordPress.org
Fonts
Google Font API
Other
Mobile Friendly